Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma

NCT07126236 · clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
80
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Collaborators